Yuguang Ban
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuguang Ban has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Jashodeep Datta
University of Miami Miller School of Medicine
98 shared publications - Nagaraj S. Nagathihalli
Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida
97 shared publications - Nipun B. Merchant
Department of Surgery and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA
97 shared publications - Austin R. Dosch
Division of Colon & Rectal Surgery, Department of Surgery, University of Miami Miller School of Medicine, Miami, Florida; Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida
96 shared publications - Iago De Castro Silva
University of Miami, Miami, FL
96 shared publications - Samara P. Singh
University of Miami, Miami, FL
96 shared publications
Latest Publications
- 29 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (6) , 1100-1109
Fifteen years of pediatric neuro-oncology trials: Insights from ClinicalTrials.gov to optimize future design
Background: Pediatric brain tumors are the leading cause of cancer-related mortality in children. Despite therapeutic advances, outcomes remain poor, and trial conduct is challenged by disease rarity, limited accrual pools, and complex multimodal regimens. Premature trial termination compounds these challenges, wasting resources and delaying progress. A comprehensive evaluation of the US pediatric neuro-oncology trial landscape and determinants of early discontinuation has not been performed. Methods: We queried ClinicalTrials.gov for US-based interventional pediatric neuro-oncology trials initiated between January 1, 2010, and December 31, 2024. Trials were categorized by design features, tumor type, sponsor, and consortium involvement. Temporal trends, trial duration, and reasons for discontinuation were analyzed. Multivariable Cox proportional hazards models assessed factors associated with trial completion among trials initiated between 2010 and 2019. Results: Of 819 identified trials, 243 met inclusion criteria. Most trials were early phase (phase 1/1-2, 69.5%) and focused on recurrent/progressive disease (68.3%), with targeted therapy (53.9%) and immunotherapy (26.3%) most common. Trial opening declined significantly over time (Poisson regression, P < .001), although the proportion of closed trials remained stable (χ² P = .97). Mean time to accrual was 4.8 ± 1.2 years, with modest improvement after 2018. Among 52 (21.4%) prematurely closed trials, poor accrual was the leading reason (50%), followed by funding issues (19.2%). Multivariable analysis identified greater site numbers decreasing the risk of premature discontinuation (hazard ratio = 0.55; 95% CI, 0.35-0.83). Conclusions: Multisite reach is a key determinant of trial persistence. Strategies to optimize accrual and reduce early termination should prioritize interinstitutional networks and trial platform site networks.
- 29 May 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
- Vol. 13 (6) , 1100-1109
Fifteen years of pediatric neuro-oncology trials: Insights from ClinicalTrials.gov to optimize future design
Background: Pediatric brain tumors are the leading cause of cancer-related mortality in children. Despite therapeutic advances, outcomes remain poor, and trial conduct is challenged by disease rarity, limited accrual pools, and complex multimodal regimens. Premature trial termination compounds these challenges, wasting resources and delaying progress. A comprehensive evaluation of the US pediatric neuro-oncology trial landscape and determinants of early discontinuation has not been performed. Methods: We queried ClinicalTrials.gov for US-based interventional pediatric neuro-oncology trials initiated between January 1, 2010, and December 31, 2024. Trials were categorized by design features, tumor type, sponsor, and consortium involvement. Temporal trends, trial duration, and reasons for discontinuation were analyzed. Multivariable Cox proportional hazards models assessed factors associated with trial completion among trials initiated between 2010 and 2019. Results: Of 819 identified trials, 243 met inclusion criteria. Most trials were early phase (phase 1/1-2, 69.5%) and focused on recurrent/progressive disease (68.3%), with targeted therapy (53.9%) and immunotherapy (26.3%) most common. Trial opening declined significantly over time (Poisson regression, P < .001), although the proportion of closed trials remained stable (χ² P = .97). Mean time to accrual was 4.8 ± 1.2 years, with modest improvement after 2018. Among 52 (21.4%) prematurely closed trials, poor accrual was the leading reason (50%), followed by funding issues (19.2%). Multivariable analysis identified greater site numbers decreasing the risk of premature discontinuation (hazard ratio = 0.55; 95% CI, 0.35-0.83). Conclusions: Multisite reach is a key determinant of trial persistence. Strategies to optimize accrual and reduce early termination should prioritize interinstitutional networks and trial platform site networks.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials from Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer
Supplementary Methods Supplementary Figures with legends Supplementary Tables S2, S4, S5-7
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials from Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer
Supplementary Methods Supplementary Figures with legends Supplementary Tables S2, S4, S5-7
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer
Differentially expressed pathways comparing transcriptomes in KRAS-TP53 co-altered (n=23) and KRAS-altered/TP53WT (n=5) derived from Cancer Cell Line Encyclopedia
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer
Differentially expressed pathways comparing transcriptomes in KRAS-TP53 co-altered (n=23) and KRAS-altered/TP53WT (n=5) derived from Cancer Cell Line Encyclopedia
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Supplementary Methods Supplementary Figures with legends Supplementary Tables S2, S4, S5-7
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Supplementary Methods Supplementary Figures with legends Supplementary Tables S2, S4, S5-7
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Differentially expressed pathways comparing transcriptomes in KRAS-TP53 co-altered (n=23) and KRAS-altered/TP53WT (n=5) derived from Cancer Cell Line Encyclopedia
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Differentially expressed pathways comparing transcriptomes in KRAS-TP53 co-altered (n=23) and KRAS-altered/TP53WT (n=5) derived from Cancer Cell Line Encyclopedia
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Differentially expressed pathways comparing transcriptomes in KRAS-TP53 co-altered (n=23) and KRAS-altered/TP53WT (n=5) derived from Cancer Cell Line Encyclopedia
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Differentially expressed pathways comparing transcriptomes in KRAS-TP53 co-altered (n=23) and KRAS-altered/TP53WT (n=5) derived from Cancer Cell Line Encyclopedia
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Materials from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Supplementary Methods Supplementary Figures with legends Supplementary Tables S2, S4, S5-7
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Supplementary Methods Supplementary Figures with legends Supplementary Tables S2, S4, S5-7
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer
Co-occupied and unique target genes shared between Creb and RNApol-II in chromatin immunoprecipitation and sequencing (ChIP-seq) experiments performed in murine Kras-Trp53 cooperative KPC pancreatic cancer cells